NICE’s Nod To Arzerra In CLL A Prelude To Rivalry With Gazyvaro, MabThera
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s NICE has given the nod to GSK’s Arzerra (ofatumumab) for first-line CLL, making an eventual rivalry with Roche’s Gazyvaro and potentially revived MabThera a possibility.